High-dose psilocybin shows promise for depression treatment

Johnson & Johnson’s nipocalimab (M-281) is under clinical development in Phase II for rheumatoid arthritis. Credit: one photo via Shutterstock. The patent for Janssen’s second-generation,

The FDA on Thurs­day ap­proved Io­n­is and As­traZeneca’s treat­ment for a fa­tal neu­rode­gen­er­a­tive dis­ease as the pair joins a space long dom­i­nat­ed by Al­ny­lam’s siR­NA med­i­cines.